CLINICAL_TRIALS
trial_result
· 2013-12-02
Clinical Trial Update: A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) [Phase 3]
Summary
A Phase 3 safety and efficacy study of oral cladribine in relapsing-remitting multiple sclerosis has completed; results were posted in 2013.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: EMD Serono | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Status: COMPLETED | Results posted: 2013-12-02